Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$5.08.

  • Madrigal Pharmaceuticals' EPS (Basic) fell 325.2% to -$5.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.89, marking a year-over-year increase of 4860.45%. This contributed to the annual value of -$21.9 for FY2024, which is 955.81% down from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' EPS (Basic) stood at -$5.08, which was down 325.2% from -$1.9 recorded in Q2 2025.
  • Madrigal Pharmaceuticals' EPS (Basic)'s 5-year high stood at -$1.9 during Q2 2025, with a 5-year trough of -$7.38 in Q1 2024.
  • Moreover, its 5-year median value for EPS (Basic) was -$4.23 (2023), whereas its average is -$4.46.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' EPS (Basic) tumbled by 7446.81% in 2024 and then skyrocketed by 7323.94% in 2025.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' EPS (Basic) stood at -$3.9 in 2021, then fell by 28.41% to -$5.01 in 2022, then fell by 19.77% to -$6.0 in 2023, then surged by 53.48% to -$2.79 in 2024, then plummeted by 81.88% to -$5.08 in 2025.
  • Its EPS (Basic) was -$5.08 in Q3 2025, compared to -$1.9 in Q2 2025 and -$3.32 in Q1 2025.